Summary of Compugen Conference Call Company Overview - **Company**: Compugen (NasdaqCM:CGEN) - **Industry**: Biotechnology, specifically in immuno-oncology - **Key Focus**: Computational AI-based target discovery for new drug targets Core Points and Arguments 1. **Unique Computational Platform**: Compugen utilizes a validated computational platform to identify first-in-class drug targets in immuno-oncology, including TIGIT and PVRIG [3][4] 2. **Pipeline Assets**: The company has two wholly owned assets, COM-902 (TIGIT blocker) and COM-701 (anti-PVRIG antibody), and has licensed COM-902 to AstraZeneca for use in their bispecific therapy [4][34] 3. **Clinical Trials**: - COM-701 is being evaluated in recurrent platinum-sensitive ovarian cancer, with promising early clinical signals observed, particularly in PD-1 negative patients [5][6][7] - The trial design includes an adaptive approach with a control arm expected to show a median progression-free survival (PFS) of 5.5 months [11][12] - Results from the trial are anticipated in Q1 2027 [12][18] 4. **Biological Mechanism**: PVRIG inhibition is believed to significantly increase T cell presence in the tumor microenvironment, which is critical for efficacy in ovarian cancer [6][9] 5. **Regulatory Considerations**: A three-month improvement in PFS over the control arm could initiate discussions with the FDA regarding accelerated approval due to the unmet need in this patient population [23][24] 6. **Partnership with AstraZeneca**: Compugen has received $30 million in milestones from AstraZeneca and is eligible for an additional $170 million, along with mid-single digit tiered royalties from potential sales of volrustomig [42][44] Additional Important Information 1. **Competitive Landscape**: Compugen is currently the only company with a PVRIG targeting antibody in clinical trials, following GSK's discontinuation of their PVRIG program [28][31] 2. **TIGIT Development**: The company has paused new trials for COM-902 due to ongoing debates in the community regarding TIGIT therapies, but sees future potential based on AstraZeneca's promising results [34][38] 3. **IL-18BP Asset**: Compugen has licensed an IL-18BP blocker to Gilead, which is currently in phase one trials, with a unique mechanism to activate IL-18 in the tumor microenvironment [50][51] 4. **Cash Runway**: Compugen has a cash runway of approximately two years, extending into Q3 2027, allowing for the continuation of current trials without additional income [61] Conclusion Compugen is positioned as a pioneer in computational drug discovery within the immuno-oncology space, with a robust pipeline and strategic partnerships that could lead to significant advancements in cancer treatment. The upcoming trial results and ongoing collaborations will be critical in shaping the company's future trajectory and market position.

Compugen (NasdaqCM:CGEN) Q3 2025 Earnings Call November 10, 2025 08:30 AM ET Company ParticipantsEran Ophir - President and CEODavid Silberman - CFOYvonne Naughton - VP and Head of Investor Relations and Corporate CommunicationsMichelle Mahle - CMOConference Call ParticipantsStephen Willey - AnalystDaina Graybosch - Senior Research AnalystSwayampakula Ramakanth - AnalystAsthika Goonewardene - AnalystLeland Gershell - Senior AnalystOperatorLadies and gentlemen, thank you for joining us today. Welcome to the ...

Compugen (NasdaqCM:CGEN) Q3 2025 Earnings Call November 10, 2025 08:30 AM ET Company ParticipantsEran Ophir - President and CEODavid Silberman - CFOYvonne Naughton - VP and Head of Investor Relations and Corporate CommunicationsMichelle Mahle - CMOConference Call ParticipantsStephen Willey - AnalystDaina Graybosch - Senior Research AnalystSwayampakula Ramakanth - AnalystAsthika Goonewardene - AnalystLeland Gershell - Senior AnalystOperatorLadies and gentlemen, thank you for joining us today. Welcome to the ...

Compugen (NasdaqCM:CGEN) Q3 2025 Earnings Call November 10, 2025 08:30 AM ET Speaker0Ladies and gentlemen, thank you for joining us today. Welcome to the Compugen Third Quarter 2025 Results Conference Call. At this time, all participants are in the listen-only mode. An audio webcast of this call is available in the investor section of Compugen's website, www.cgen.com. As a reminder, today's call is being recorded. I would now like to introduce Yvonne Naughton, VP, Head of Investor Relations and Corporate Co ...

Core Insights - Compugen reported a quarterly loss of $0.07 per share, better than the Zacks Consensus Estimate of a loss of $0.09, representing an earnings surprise of +22.22% [1] - The company posted revenues of $1.89 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 14.43% and down from $17.13 million year-over-year [2] - Compugen shares have increased by approximately 5.9% since the beginning of the year, underperforming the S&P 500's gain of 14.4% [3] Earnings Outlook - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the next quarter is -$0.09 on revenues of $4.91 million, and for the current fiscal year, it is -$0.34 on revenues of $12.34 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Compugen belongs, is currently ranked in the top 36% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Compugen's stock performance [5][6]

Core Insights - Compugen Ltd. reported its third quarter 2025 financial results, highlighting a significant decrease in revenue compared to the same period in 2024, alongside advancements in its clinical pipeline and a strong cash position [1][5][3]. Financial Performance - Revenue for Q3 2025 was approximately $1.9 million, a decrease from $17.1 million in Q3 2024, primarily due to the recognition of upfront and milestone payments from Gilead [5]. - Research and Development (R&D) expenses were approximately $5.8 million in Q3 2025, down from $6.3 million in Q3 2024 [6]. - General and Administrative (G&A) expenses were approximately $2.2 million in Q3 2025, compared to $2.6 million in Q3 2024 [6]. - The net loss for Q3 2025 was approximately $6.98 million, or $0.07 per share, contrasting with a net profit of approximately $1.28 million, or $0.01 per share, in Q3 2024 [7]. Clinical Developments - Compugen's COM701, an Fc-reduced anti-PVRIG antibody, showed promising Phase 1 data at ESMO 2025, indicating it is well tolerated and delivers durable responses in heavily pretreated platinum-resistant ovarian cancer patients [2][4]. - The ongoing MAIA-ovarian platform trial is evaluating COM701 maintenance therapy in platinum-sensitive ovarian cancer, with interim analysis expected in Q1 2027 [4]. - AstraZeneca presented positive results for its rilvegostomig program at ESMO 2025, reinforcing the potential of Fc-reduced anti-TIGIT antibodies [2][4]. Financial Position - As of September 30, 2025, Compugen had approximately $86.1 million in cash and cash equivalents, sufficient to fund operations into Q3 2027 [3]. - The company has no debt and recently raised approximately $1.6 million through the sale of shares [3]. Strategic Partnerships - Compugen has established partnerships with AstraZeneca and Gilead, which could provide over $1 billion in potential milestones and royalties, enhancing the company's financial outlook and pipeline development [2][3].

Accessibility StatementSkip Navigation Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive AI/ML powered computational discovery platform (Unigen) to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has two proprietary product candidates in Phase 1 development: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatm ...

Core Insights - Compugen Ltd. is set to release its third quarter 2025 financial results on November 10, 2025, before U.S. markets open, followed by a conference call at 8:30 AM ET to discuss the results and provide a corporate update [1]. Company Overview - Compugen is a clinical-stage cancer immunotherapy company that utilizes a predictive AI/ML-powered computational discovery platform named Unigen to identify new drug targets and biological pathways for cancer immunotherapies [3]. - The company has two proprietary product candidates in Phase 1 development: COM701, an anti-PVRIG antibody, and COM902, an antibody targeting TIGIT for solid tumors [3]. - Rilvegostomig, a PD-1/TIGIT bispecific antibody, is in Phase 3 development by AstraZeneca under a licensing agreement, while GS-0321, an anti-IL-18 binding protein antibody, is also in Phase 1 development and licensed to Gilead [3]. - Compugen's therapeutic pipeline includes early-stage immuno-oncology programs aimed at activating the immune system against cancer [3]. - The company is headquartered in Israel with additional offices in San Francisco, CA, and its shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN [3].

Group 1 - Compugen Ltd. (NASDAQ: CGEN) is an immuno-oncology biotech utilizing its Unigen platform for discovering immune checkpoints, drug candidates, and biomarkers [1] - The Unigen platform is based on Artificial Intelligence and Machine Learning technologies [1] Group 2 - The article does not provide any financial performance data or specific investment recommendations related to Compugen Ltd. [2][3]

Core Insights - Compugen Ltd. announced a pooled analysis supporting the anti-tumor activity and safety profile of COM701 in heavily pre-treated patients with platinum-resistant ovarian cancer, published as an abstract by the European Society of Medical Oncology (ESMO) [1][2][3] Company Developments - The pooled analysis included 60 evaluable patients from prior COM701 Phase 1 clinical trials, focusing on clinical benefits and progression-free survival data [2][3] - COM701 demonstrated good tolerance and durable responses, especially in patients without liver metastases, indicating a potential for lower disease burden and less immunosuppressive tumor microenvironment [3] - Compugen is conducting the MAIA-ovarian trial to evaluate COM701 as maintenance therapy in relapsed platinum-sensitive ovarian cancer, with an interim analysis planned once data from approximately 60 participants is available [3][6] Future Plans - The MAIA-ovarian trial aims to assess the median progression-free survival, with sites activated in the U.S., Israel, and France to support enrollment [3][6] - Compugen anticipates interim analysis results by the end of 2026, with sufficient cash flow to support operations into 2027 [3][6] Industry Context - ESMO 2025 will feature presentations from companies with differentiated Fc-reduced TIGIT programs, including oral presentations from Compugen's partner AstraZeneca [5]